Bronchoscopic lung volume reduction (BLVR) methods have emerged as a new treatment option for patients with severe emphysema. Endobronchial valves and coils have been extensively studied. This review assesses efficacy, safety, and cost effectiveness of the BLVR procedures (stent, valves, vapor ablation, endobronchial coils, lung sealant) in patients with severe emphysema. Databases were searched until October 2016, and randomized controlled trials (RCTs) comparing available BLVR procedures to standard medical care or sham bronchoscopy were included. Random effect model and generic inverse variance approach were used for meta-analysis. Out of 381 identified records, 16 RCTs were included. As compared to recommended medical care or sham bronchoscopy, the BLVR procedures are more effective in improving quality of life [SGRQ score (WMD=−6.38; −9.12 to −3.65)] and 6MWT (WMD=24.21; 9.68-38.74) and percentage FEV 1 (WMD=10.48; 7.07-13.89). Increased risk of serious adverse events (RR=2.18; 1.63-2.93), specifically for chronic pulmonary obstructive disease exacerbations and lower respiratory tract infection combined (RR=1.37; 1.07-1.75), were observed with bronchoscopic interventions, while there was no difference in number of deaths (RR=1.25; 0.79-1.99) and respiratory failure (RR=1.13; 0.57-2.21). The BLVR procedures, especially endobronchial coils, were found to be effective in the management of patients with severe emphysema irrespective of collateral ventilation. However, characterization of patients who would be most benefited from these procedures is required, and effectiveness of these procedures in long run needs to be established.
INTRODUCTION
Chronic pulmonary obstructive disease (COPD) is a chronic inflammatory disease of the airways and the lungs. It is expected to be the third leading cause of death by 2020 [1] . It is characterized by a spectrum of small airway abnormalities of which emphysema is a major pathological feature. It is associated with alveolar destruction and loss of surrounding elastic tissue and elastic recoil of the lungs that leads to air trapping and increased lung volumes. These altered pathophysiological changes lead to static and dynamic hyperinflation that causes dyspnea, decreased exercise capacity, and impaired quality of life.
Lung volume reduction surgery (LVRS) improves lung function, quality of life, and survival in a specific subset of patients having advanced heterogeneous upper lobe emphysema, but is associated with considerable post-operative complications and mortality (7.9% after 90 days) [2] . Bronchoscopic lung volume reduction (BLVR) procedures appear promising as compared to standard medical care, and safe alternative to LVRS. Endobronchial valves (EBV), one of the most extensively studied bronchoscopic approach, appear to be promising in patients with complete inter-lobar fissure integrity and no collateral ventilation [3] . Other available BLVR modalities of notable interest are endobronchial coils (EBC) [4, 5] , thermal vapor ablation (TVA) [6, 7] , emphysematous lung sealant (ELS) [8] , and Exhale Airway Stents for Emphysema (EASE) [9] . As evident need exists to assess role of available minimally invasive BLVR procedures, this review was conducted to evaluate their efficacy and safety in management of patients with advanced emphysema.
Science Citation Index Expanded and Cochrane databases (until July 31, 2018) . Randomized controlled trials (RCTs) assessing efficacy and safety of the BLVR procedures compared to recommended medical care were included in this review. Search strategy using the following search terms and their associated medical subject headings was developed: 'emphysema', 'bronchoscopic lung volume reduction', 'endobronchial coil', 'Lung volume reduction coil' and 'airway bypass', 'bronchoscopy glue', 'bronchoscopy sealant', 'bronchoscopy vapor', 'Emphysema airway stent', 'intrabronchial valves' (Table 1) .
Two investigators independently screened title and abstract of all search results. Any study found as potentially eligible was read by both authors to determine inclusion. Eligibility criteria were RCTs evaluating BLVR methods compared to recommended medical care or sham bronchoscopy. Both investigators also searched ClinicalTrials.gov and WHO International Clinical Trials Registry Platform search portal without time limits to include any ongoing trials.
Inclusion/exclusion criteria for included trials were: 1) study population: patients with COPD with severe emphysema; 2) any BLVR procedures; 3) study design: an RCT. Studies on animal trial or preclinical studies and non-original articles such as reviews, editorials, letters, and comments were excluded. To resolve disagreements and reaching consensus, multiple rounds of discussion with other co-authors were held.
Data Extraction
Data extraction form was adapted from the Cochrane Airway Review group [11] . It was pilot tested on two included randomly selected studies, and refined accordingly. Two review authors extracted the data that was cross-checked by another review author.
Primary efficacy outcomes for which data were extracted was improvement in patient health status, that is, healthrelated quality of life measured using the St George's Respiratory Questionnaire (SGRQ) score, which ranges from 0 to 100, with a higher score indicating worse quality of life; exercise capacity measured as 6 Minute Walk Distance (6MWD); and Percentage predicted FEV 1 .
Primary safety outcomes assessed were patients experiencing serious adverse events (SAE) reported as deaths, need of hospitalization or any intervention because of occurrence of pneumothorax, COPD exacerbations, lower respiratory infections, hemoptysis, or respiratory failure.
For dichotomous outcome, the number of participants experiencing the event and total in each group was recorded, while for continuous outcomes between-group differences for change in mean and SD at maximum follow-up duration in study trial was included.
Quality Assessment
Methodological quality was independently assessed by two reviewers in accordance with published guidelines [12] . The components assessed were random sequence generation, allocation concealment, blinding of intervention (participants/investigator), blinding of outcome assessment, complete reporting of outcome data, and selective reporting and other bias. Risk of bias for each study was assessed, and in case of any disagreement, the authors resolved it through discussions and building consensus.
Data Synthesis
We used the REVMAN software (Version 5.3. Copenhagen, Denmark) (13) for outcome analysis at the longest follow-up time point. Dichotomous outcomes were pooled as summary relative risk (RR) with 95% confidence intervals (CI), and mean difference with standard error was calculated for continuous outcomes through generic inverse variance (GIV) in which the treatment effect is significant at the 5% level. Heterogeneity between trials was quantified by I 2 statistic roughly interpreted as follows: <=25%: absent; 26%-39%: unimportant, 40%-60%: moderate; 60%-100%: substantial heterogeneity (12) .
Meta-analysis was performed using the random-effects model, as the studies included are not functionally identical. The subjects and intervention performed in studies are different, and thus common effect size cannot be assumed [14] .
RESULTS
Out of 381 records identified, 16 RCTs were included [9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , and 1 RCT by Hartman et al. [30] was excluded as it was subgroup analysis of the patients included in a study done by Klooster et al. (Figure 1 ) [23] . The study conducted by Gompelmann et al. [19] on patients with positive collateral ventilation was a subpart of the TVA study done by Herth et al. [21] . It was included in the final analysis as the study has shown positive results with vapor ablation therapy in patients with positive collateral ventilation, and the weight of the study is only 4.5%. Excluding from the final analysis did not change the overall effect estimate of all the interventions. A total of 1187 patients were studied for the BLVR interventions and compared to either recommended medical care as per international guidelines or Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria or sham bronchoscopy (828 patients) [31] A sample size of more than 100 in either or both groups was included in five trials [9, 16, 25, 26, 29] . The trials included in the meta-analysis followed patients for duration of 3-12 months.
Risk of Bias
A tool from the Cochrane Collaboration was used to assess the risk of bias of each study. Low risk of performance and detection bias by comparing BLVR to sham bronchoscopy was observed for EBV [17, 22] , airway stent [9] , and IBV trial [24, 29] . Risk of bias related to randomization, allocation concealment, attrition, and selective reporting was found to be low for the majority of trials (Figure 2 ).
Efficacy of Interventions
For studying efficacy outcome, lung sealant trial (15) was excluded from efficacy meta-analysis as it was prematurely terminated and possessed a high risk of bias ( Figure 2 ). Quality of evidence for the efficacy of intervention was assessed for patients with no collateral ventilation undergoing the bronchoscopic procedure for EBV (Table 3 ) and for EBC ( (Figure 3a) . (Figure 3b ).
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Outcomes Related to Lung Function
Percent change in % predicted FEV 1 Pooled analysis for mean change in % predicted FEV 1 (Figure 3c ). 
Safety of bronchoscopic intervention
All 15 studies were included for meta-analysis as reporting of adverse events is unlikely to get affected due to high risk of bias.
Serious Adverse Events
Serious adverse events were defined as incidence of deaths or events that required or prolonged hospitalization or were life-threatening. (Figure 4a ).
Death and Respiratory Failure
No significant difference was observed in the risk of mortality ( Figure 4b ) and respiratory failure requiring mechanical ventilation (Figure 4c ) in both pooled and subgroup analysis (p>0.05). Heterogeneity was found to be absent (I 2= 0), and the quality of evidence was moderate for both EBC (Table 4) and EBV (Table 3) . 
Combined Episodes of COPD Exacerbations and Lower Respiratory Infections (LRTI)
Publication bias
Publication bias was low as the funnel plot for 16 studies appears to be symmetrical around the intervention effect estimate. This review includes only randomized trials, and does not take into account the pilot studies and cohort studies previously published for one or more bronchoscopic interventions. As all types of studies were published for bronchoscopic intervention, publication bias is not detected.
Clinical and Research Consequences
Despite the maximal pharmacological treatment and rehabilitation, the patients with COPD with moderate to severe emphysema remain symptomatic. LVRS has shown long-term benefit only in a specific subset of patients with considerable post-operative morbidity and mortality, and thus the BLVR procedures have evolved in the quest of a safer treatment option for patients with advanced emphysema.
Our systematic review highlights the safety and efficacy of the BLVR procedures over a period of 3-12 months in managing patients with advanced severe emphysema. The inclusion of randomized trials for comparing the BLVR procedures to medical care or sham bronchoscopy provides robust estimates regarding benefits of existing methods as compared to published meta-analyses [32, 33] . The strengths of our metaanalysis are that the GIV approach was used. The change from baseline scores was compared for both groups for patient-centric and lung function outcomes using random effect model to account for between studies variance and to ensure generalizability of results.
Earlier trials [20, 26] for EBV suggested higher efficacy in patients with no collateral ventilation for both heterogeneous and homogeneous emphysema. In this review, to determine the efficacy of EBV, post-hoc analysis data of patients with no collateral ventilation in Herth et al. [20] and Sciurba FC [26] trials were included along with other trials [16, 17, 20, 22, 23, 28] that studied only patients with no collateral ventilation.
In the intervention group, significant improvement was observed, and minimal clinically important difference (MCID) was achieved for the quality of life, 6MWD, and percentage change in predicted FEV 1 . Higher risk of serious respiratory adverse events especially pneumothorax and Figure 2 . Risk of bias summary for bronchoscopic lung volume reduction interventions studies in patients with severe emphysema COPD and LRTI exacerbations is also significantly high in the intervention group, and it underscores the need for careful and planned follow-up in patients recruited for EBV.
Pooled mean differences for EBCs showed statistically significant improvement in all studied parameters and more than respective MCIDs for SGRQ score and 6MWT. Suitability of EBCs in patients who are ineligible for either Turk Thorac J 2019; 20(1): [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] 52 Figure 3a . Efficacy outcomes of bronchoscopic lung volume reduction interventions in patients with severe emphysema: SGRQ Score LVRS or EBVs and evidence of both efficacy and safety up to 12 months of follow-up is noteworthy. High risk of LRTI (pneumonia) reported in EBC is attributed to local inflammation, ischemia, and scarring of lung parenchyma and not due to infections [25] . Similarly, observed the high risk of pneumothorax is associated with atelectasis, and it rarely requires surgical intervention for management [34] . EBCs is not strong as the two out of three included trials with large sample size has a high risk of performance bias (participants not blinded to intervention) and detection bias [18, 25] . Higher risk of serious respiratory adverse events in EBC group emphasizes the need for planned follow-up in patients opting for EBC.
Turk Thorac J 2019; 20(1): [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] 54 Figure 3c . Efficacy outcomes of bronchoscopic lung volume reduction interventions in patients with severe emphysema: Percentage predicted FEV 1 As reported by Kumar et al. [32] and Iftikhar et al. [33] , segmental volume reduction by vapor ablation may appear as a promising approach in patients of upper lobe emphysema with positive collateral ventilation, but it needs to be further substantiated with large sample size randomized trials over a longer duration. Similar to Iftikhar et al. [33] results regarding the efficacy of stents in patients with severe homogeneous emphysema were observed in our review. Milenkovic et al. [35] reviewed bronchoscopic administration of lung sealants as an effective approach in patients with upper lobe emphysema with both heterogeneous and homogeneous distribution in patients with advanced emphysema. This could not be validated by this review because of the presence of limited evidence in form of prematurely terminated single trial with small sample size and high attrition (15) .
Substantial heterogeneity (I 2 >50%) was observed for outcomes possibly due to varied inclusion and exclusion criteria of patients as per pattern of emphysema; the severity of disease (predicted FEV 1 , RV and TLC); smoking status and compliance Figure 4c . Safety outcomes of bronchoscopic lung volume reduction interventions in patients with severe emphysema: Respiratory failure requiring mechanical ventilation to pulmonary rehabilitation guidelines among participants.
Also, varied definitions were adopted to estimate both efficacy and safety outcomes. For 6MWT, MCID of 54 m assessed by one trial [18] is more than double of the recommended MCID values for 6MWD (between 25 and 30 m) [36] . Standardized inclusion and exclusion criteria and outcome definition in future trials are thus warranted to assess clinical efficacy and safety of the BLVR interventions. The included trials did not account for the influence of co-morbidities on studied outcomes, and thus the observed effect in our review was unable Figure 4d . Safety outcomes of bronchoscopic lung volume reduction interventions in patients with severe emphysema: COPD exacerbations and LRTI to report outcomes as per the health profile of participants. Also, the results of included trials are not stratified by age, sex, ethnicity, smoking status, and severity of disease that may reportedly influence studied outcomes [37] [38] [39] . Thus, this review cannot suggest optimum age, stage of disease, ethnic origin, and sex of a patient for whom the BLVR procedures will be more efficacious with minimum side effects.
Directions for future research
We suggest that the aforementioned limitations should guide future research especially those regarding EBV and EBCs. Future research should focus on optimizing four Ps for better interpretation of evidence, and to reach generalizability regarding available evidence. First P is recognizing patient characteristics by including a large sample size from multiple sites, both from developed and developing economies to stratify patient subgroups and thus getting maximum benefits from the BLVR procedures. Second P and third P are optimizing suitable BLVR Procedure and Provider experience and expertise in carrying out the procedure. This should be complemented with the fourth P in form of planned followup for early and successful diagnosis and management of potential complications either due to disease or due to the procedure. At present, evidence of the BLVR interventions is mainly available through studies carried out by an expert group in specialized centers. Research on patient population in less specialized centers and from developing economies is needed to justify the role of the BLVR interventions globally.
Bronchoscopic reduction of lung volume has emerged as a promising intervention for patients with advanced severe emphysema. Patient quality of life, exercise capacity, and lung function tests have been observed to improve with EBV at the cost of increased respiratory adverse events in patients with no collateral ventilation, and existing quality of evidence is high. EBC and TVA appear to be promising modalities, and large sample trials are needed in future to establish robust evidence. Optimizing patient selection for the specific bronchoscopic procedure with planned follow-up care to manage the higher risk of serious respiratory adverse events can prove beneficial for patients with advanced severe emphysema over standard medical care.
Key Message
Among patients with advanced severe emphysema, endobronchial valves and endobronchial coils have shown promising short-term improvement in important disease outcomes with increased risk of serious adverse events. Endobronchial coils are effective in both heterogeneous and homogeneous emphysema irrespective of collateral ventilation status, while endobronchial valves are effective only in patients without collateral ventilation. Among other modalities, bronchoscopic thermal vapor ablation appears promising, but it has not yet been adequately studied to derive any robust conclusion, while intra-bronchial valves, airway stents, and lung sealants are of no proven benefit. Although increased mortality was not observed with any of bronchoscopic procedures, long-term data are required to further substantiate the current findings.
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